- Home
- AGEN vs AXR Comparison
AGEN vs AXR Comparison
Compare AGEN & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- AXR
- Stock Information
- Founded
- AGEN 1994
- AXR 1961
- Country
- AGEN United States
- AXR United States
- Employees
- AGEN N/A
- AXR N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- AXR Homebuilding
- Sector
- AGEN Health Care
- AXR Real Estate
- Exchange
- AGEN Nasdaq
- AXR Nasdaq
- Market Cap
- AGEN 142.8M
- AXR 117.0M
- IPO Year
- AGEN 2000
- AXR N/A
- Fundamental
- Price
- AGEN $4.55
- AXR $27.99
- Analyst Decision
- AGEN Buy
- AXR
- Analyst Count
- AGEN 2
- AXR 0
- Target Price
- AGEN $14.50
- AXR N/A
- AVG Volume (30 Days)
- AGEN 395.5K
- AXR 13.1K
- Earning Date
- AGEN 11-11-2025
- AXR 09-09-2025
- Dividend Yield
- AGEN N/A
- AXR N/A
- EPS Growth
- AGEN N/A
- AXR 40.98
- EPS
- AGEN N/A
- AXR 2.48
- Revenue
- AGEN $101,706,000.00
- AXR $48,454,000.00
- Revenue This Year
- AGEN $60.49
- AXR $12.31
- Revenue Next Year
- AGEN N/A
- AXR $8.40
- P/E Ratio
- AGEN N/A
- AXR $10.12
- Revenue Growth
- AGEN N/A
- AXR N/A
- 52 Week Low
- AGEN $1.38
- AXR $17.60
- 52 Week High
- AGEN $7.34
- AXR $39.68
- Technical
- Relative Strength Index (RSI)
- AGEN 48.05
- AXR 77.68
- Support Level
- AGEN $4.36
- AXR $20.57
- Resistance Level
- AGEN $5.20
- AXR $25.83
- Average True Range (ATR)
- AGEN 0.27
- AXR 1.46
- MACD
- AGEN 0.04
- AXR 0.66
- Stochastic Oscillator
- AGEN 40.91
- AXR 100.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.